Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.16 USD | +2.37% | +4.85% | +22.73% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 135M |
---|---|---|---|---|---|
Net income 2024 * | -30M | Net income 2025 * | -45M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.5
x | P/E ratio 2025 * |
-3.96
x | Employees | 28 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.74% |
Latest transcript on Corvus Pharmaceuticals, Inc.
1 day | +2.37% | ||
1 week | +4.85% | ||
1 month | +39.35% | ||
3 months | -3.57% | ||
6 months | +41.18% | ||
Current year | +22.73% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Miller
CEO | Chief Executive Officer | 73 | 14-01-26 |
Leiv Lea
DFI | Director of Finance/CFO | 70 | 14-01-26 |
James Rosenbaum
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Miller
CEO | Chief Executive Officer | 73 | 14-01-26 |
Ian Clark
BRD | Director/Board Member | 62 | 17-01-02 |
Terry Gould
BRD | Director/Board Member | 67 | 14-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 2.16 | +2.37% | 55,304 |
24-05-30 | 2.11 | +0.48% | 132,142 |
24-05-29 | 2.1 | +3.96% | 123,166 |
24-05-28 | 2.02 | -1.94% | 458,882 |
24-05-24 | 2.06 | -0.48% | 169,009 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.73% | 135M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- CRVS Stock